The FDA agrees that the Company may follow 505(b)(2) regulatory pathway to non-invasively treat basal cell carcinoma (BCC) of ...
By combining our strengths, we aim to change how science advances, unlocking new ways to accelerate scientific progress.” “We ...
The thalassemia market is primarily driven by regular blood transfusions and iron chelation therapies, which help manage anemia and prevent iron overload. Curative treatments, such as stem cell ...
Gloperba® is the subject of an exclusive, transferable license to use the registered trademark by Scilex Holding Company. ELYXYB® is a registered trademark owned by Scilex Holding Company. Scilex Bio™ ...
Innovent Biologics' newly launched weight-loss drug is making inroads in its home market of China, ramping up competition ...
A novel substance disrupts stress management in cancer cells and offers new therapeutic approaches to treating tumours.
Arch Biopartners Inc. is a therapeutic biotech company developing novel drugs for acute and chronic kidney diseases. The Company is advancing an integrated pipeline that includes new treatments ...
Siemens and Merck hope AI and other technologies can close production gaps and tackle rising costs in the drug market.
Biogen to drive end-to-end development and commercialization of ThecaFlex DRx™, an investigational implantable device for intrathecal delivery of ...
By merging biodefense preparedness with pharmaceutical innovation, Lunai Bioworks Inc. is building a dual-purpose transformer for safe generative biology. This positions the company as a category ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback